TCA
BMRN icon

Transcend Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Transcend Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Buy
+3,912
New +$214K 0.02% 740
2025
Q4 		– Sell
-4,827
Closed -$261K – 698
2025
Q3 		$261K Buy
4,827
+895
+23% +$51.2K 0.02% 585
2025
Q2 		$216K Buy
+3,932
New +$232K 0.02% 564

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Transcend Capital Advisors's BMRN Position: Q2 2026 in Review

Transcend Capital Advisors opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 3,912 shares worth $224K. The stake represents 0.02% of the portfolio and ranks #740 among its holdings. This is a return to the name: Transcend Capital Advisors previously reported a position in BMRN as recently as Q3 2025.

Transcend Capital Advisors first reported a position in BMRN in Q2 2025 and has held it in 3 quarters since. The position peaked at $261K in Q3 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Transcend Capital Advisors held 3,912 shares of BioMarin Pharmaceuticals worth $224K as of Q2 2026.
  • BioMarin Pharmaceuticals was a new Transcend Capital Advisors position in Q2 2026.
  • BioMarin Pharmaceuticals made up 0.02% of Transcend Capital Advisors's portfolio in Q2 2026, its #740 holding.
  • Transcend Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • Transcend Capital Advisors's BioMarin Pharmaceuticals position peaked at $261K in Q3 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.